Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US. 

Manufacturing process of n.c.a. Lutetium-177, ©ITM

Radiopharmaceutical Therapy (RPT) is offering several advantages over existing therapeutic strategies. The highly sought-after therapeutics require a sophisticated supply chain, as radioisotopes have short half-lives and must be delivered to patients with extreme speed and efficiency. ITM rises to this challenge as one of the largest global providers and developers of medical radioisotopes for this novel therapy.

Figure 1: Example of a process landscape; © Richter-Helm BioLogics GmbH & Co.KG

The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.

AstraZeneca Cambridge headquarters © wikipedia.org/D_Wells

French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.

Osteoporosis © Daria - stock.adobe.com

London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.

Treatment with the agonistic TREM2 antibody 4D9 leads to the formation of smaller necrotic cores (red outlines) in atherosclerotic plaques of the aortic root in Ldlr-/- mice. © Nature Cardiovascular Research

TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.

Picture: ©?Barbara Evripidou FirstAvenuePhotography.com

As cultivated meat moves closer to commercialisation, we are seeing a worrying trend of misinformation entering the public debate. This food can play a vital role in ensuring Europe’s food system is fit for the future – helping satisfy the growing demand for meat while boosting food security – but political opposition has mounted, with the Italian government taking the controversial step of banning cultivated meat.

Boehringer's broad commercial expertise and development capabilities cover the whole value chain. © Boehringer

The world of microbial product manufacturing is a complex landscape, ­driven by a diverse range of molecule formats and manufacturing processes. At the forefront of this specialty market is Boehringer Ingelheim Vienna, one global leader in biopharmaceutical development and manufacturing.

Kilger_Ute_im_Raum_small_sw_IP

In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?

© Stephanie Kath-Schorr

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.